Champions Oncology Inc.
| NASDAQ: CSBR |
| Healthcare / Biotechnology / USA |
| 7.75 | +0.1800 | +2.38% | Vol 9.44K | 1Y Perf -21.72% |
| Jun 24th, 2022 16:00 DELAYED |
| BID | 5.87 | ASK | 9.44 | ||
| Open | 7.57 | Previous Close | 7.57 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 13.50 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 74.19 | Finscreener Ranking | ★+ 44.03 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ☆ 30.68 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★+ 47.86 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 21.17 | Earnings Rating | Strong Sell | |
| Market Cap | 104.80M | Earnings Date | 28th Jul 2022 | |
| Alpha | 0.03 | Standard Deviation | 0.20 | |
| Beta | 1.03 |
Today's Price Range 7.577.75 | 52W Range 6.8111.25 | 5 Year PE Ratio Range -37.101.04K |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 2.38% | ||
| 1 Month | 5.01% | ||
| 3 Months | -8.82% | ||
| 6 Months | -3.61% | ||
| 1 Year | -21.72% | ||
| 3 Years | -3.97% | ||
| 5 Years | 191.35% | ||
| 10 Years | 57.52% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -14.65 | |||
ROE last 12 Months | 2.65 | |||
ROA (5Y Avg) | -1.18 | |||
ROA last 12 Months | 0.77 | |||
ROC (5Y Avg) | -124.35 | |||
ROC last 12 Months | 1.32 | |||
Return on invested Capital Q | 4.32 | |||
Return on invested Capital Y | 2.77 | |||
Assets Turnover | 1.20 | |||
Receivables Turnover | 4.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 757.00 | ||||
| 11.08 | ||||
| 2.83 | ||||
| 29.10 | ||||
| 26.80 | ||||
| 0.26 | ||||
| 11.50 | ||||
| 0.68 | ||||
| 103.30M | ||||
| Forward PE | 29.60 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.10 | ||||
| 1.20 | ||||
| 0.48 | ||||
| 1.04 | ||||
| - | ||||
| Leverage Ratio | 3.70 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 48.60 | ||||
| 0.60 | ||||
| 3.50 | ||||
| -2.00 | ||||
| 2.46 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 36.23M | ||||
| 2.68 | ||||
| 12.01 | ||||
| 20.97 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | 0.03 | 0.05 | 66.67 |
| Q02 2022 | 0.00 | 0.02 | - |
| Q01 2022 | 0.01 | -0.01 | -200.00 |
| Q04 2021 | 0.01 | -0.04 | -500.00 |
| Q03 2021 | 0.01 | 0.05 | 400.00 |
| Q02 2021 | 0.01 | 0.00 | -100.00 |
| Q01 2021 | 0.02 | 0.01 | -50.00 |
| Q04 2020 | 0.01 | -0.17 | -1 800.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 4/2022 QR | 0.02 | -33.33 | Negative |
| 4/2022 QR | 0.03 | -25.00 | Negative |
| 4/2022 FY | 0.08 | 14.29 | Positive |
| 4/2023 FY | 0.25 | 0.00 | - |
| Next Report Date | 28th Jul 2022 |
| Estimated EPS Next Report | 0.02 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 9.44K |
| Shares Outstanding | 13.52K |
| Shares Float | 6.94M |
| Trades Count | 118 |
| Dollar Volume | 72.67K |
| Avg. Volume | 2.54K |
| Avg. Weekly Volume | 1.68K |
| Avg. Monthly Volume | 2.06K |
| Avg. Quarterly Volume | 3.88K |
Champions Oncology Inc. (NASDAQ: CSBR) stock closed at 7.75 per share at the end of the most recent trading day (a 2.38% change compared to the prior day closing price) with a volume of 9.44K shares and market capitalization of 104.80M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 143 people. Champions Oncology Inc. CEO is Ronnie Morris.
The one-year performance of Champions Oncology Inc. stock is -21.72%, while year-to-date (YTD) performance is -7.3%. CSBR stock has a five-year performance of 191.35%. Its 52-week range is between 6.81 and 11.25, which gives CSBR stock a 52-week price range ratio of 21.17%
Champions Oncology Inc. currently has a PE ratio of 757.00, a price-to-book (PB) ratio of 11.08, a price-to-sale (PS) ratio of 2.83, a price to cashflow ratio of 29.10, a PEG ratio of 2.32, a ROA of 0.77%, a ROC of 1.32% and a ROE of 2.65%. The company’s profit margin is 2.46%, its EBITDA margin is 3.50%, and its revenue ttm is $36.23 Million , which makes it $2.68 revenue per share.
Of the last four earnings reports from Champions Oncology Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.02 for the next earnings report. Champions Oncology Inc.’s next earnings report date is 28th Jul 2022.
The consensus rating of Wall Street analysts for Champions Oncology Inc. is Strong Buy (1), with a target price of $13.5, which is +74.19% compared to the current price. The earnings rating for Champions Oncology Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Champions Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Champions Oncology Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.77, ATR14 : 0.21, CCI20 : 130.19, Chaikin Money Flow : 0.32, MACD : 0.04, Money Flow Index : 77.60, ROC : 5.01, RSI : 56.61, STOCH (14,3) : 78.26, STOCH RSI : 1.00, UO : 62.50, Williams %R : -21.74), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Champions Oncology Inc. in the last 12-months were: David Sidransky (Option Excercise at a value of $26 501), Scott R. Tobin (Option Excercise at a value of $15 900)
Champions Oncology Inc.
Champions Oncology Inc is a US-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
CEO: Ronnie Morris
Telephone: +1 201 808-8400
Address: One University Plaza, Hackensack 07601, NJ, US
Number of employees: 143
